Pacira Bolsters Genetic Medicine Capacity with Full Acquisition of GQ Bio

Pacira BioSciences, a leader in non-opioid pain therapies, has acquired the remaining 81% equity stake in GQ Bio Therapeutics GmbH for approximately $32 million. This strategic acquisition enhances Pacira's capabilities in developing genetic medicines via GQ Bio's novel HCAd gene therapy vector platform, which efficiently delivers genetic material locally with potential applications in musculoskeletal diseases. The deal eliminates $64 million in future milestone obligations, thus providing financial benefits. GQ Bio, now a wholly owned subsidiary, enhances Pacira's research portfolio and is expected to drive significant advancements in treatments for chronic pain and other conditions. The company's proprietary platform supports the development and commercialization of therapies addressing prevalent diseases like osteoarthritis and could expand into other therapeutic areas. This move underscores Pacira's 5x30 plan to transition into a leading biopharmaceutical firm and highlights the expected commercial and medical impact of genetic therapies.